Drug-induced liver injury with cholestasis. Part 2: focus on antidiabetic drugs


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Clinical use of some hypoglycemic drugs may be associated with the risk of drug - indiced cholestatic liver damage (DILI). The exact prevalence of this complication is unknown, however, there is a number of clinical cases described in the literature of glimepiride-, metformin-, glibenclamide-, glipizide-, thiazolidinediones- associated DILIs. One of the most effective and safe strategies of treating patients with drug-induced liver damage, regardless of the clinical form, but especially the cholestatic variant, is the administration of ursodeoxycholic acid (UDCA). Efficacy of this drug has a convincing evidence base, which is reflected in the clinical guidelines. The Russian Gastroenterological Association, the European Association for the Study of the Liver, as well as the Russian Scientific Medical Society of Physicians and the Scientific Society of Gastroenterologists of Russia. Among all UDCA drugs, Ursosan® (PRO. MED.CS Praha a.s., Czech Republic) stands out, which is characterized by high quality and whose effectiveness has been confirmed by real clinical practice.

Texto integral

Acesso é fechado

Sobre autores

O. Ostroumova

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

A. Pereverzev

Russian Medical Academy of Continuous Professional Education

Email: acchirurg@mail.ru
Cand. Sci. (Med.), Associate Professor, Department of Therapy and Polymorbid Pathology 2/1, build. 1, Barrikadnaya str., Moscow 125993, Russian Federation

D. Gusenbekova

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

E. Pavleeva

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Moscow, Russia

Bibliografia

  1. Omar H., Kolia J., Mangar D., Camporesi E. GUmepiride-induced cholestasis in a man with diabetes meiiitus: a case report. J Med Case Reports. 2009;3:9257. doi: 10.4076/1752- 1947-3-9257.
  2. Nammour F.E., Fayad N.F., Peikin S.R. Metformin-induced choiestatic hepatitis. Endocr Pract. 2003;9(4):307-9. doi: 10.4158/EP9.4.307.
  3. Desiiets D.J., Shorr A.F., Moran K.A., Hoitzmuiier K.C. Choiestatic jaundice associated with the use of metformin. Am J Gastroenteroi. 2001;96(7):2257-58. doi: 10.1111/j.1572-0241.2001.03972.x.
  4. Thoiakanahaiii V.N., Potti A., Heyworth M.F. Giibenciamide-induced choiestasis. West J Med. 1998;168(4):274-47.
  5. Dei-Vai A, Garrigues V, Ponce J., Benages R. Giibenciamide-induced choiestasis. J Hepatoi. 1991;13(3):375. doi: 10.1016/0168- 8278(91)90085-p.
  6. Kamai P, Bhabhra R. Giipizide Induced Hepatotoxicity: A Case Report and Review of Literature. J Diabetes Metab Disord 2019;6:028. doi: 10.24966/DMD-201X/100028.
  7. Pin to A.G., Cummings O.W., Chaiasani N. Severe but reversibie choiestatic iiver injury after piogiitazone therapy. Ann Intern Med. 2002;137(10):857. doi: 10.7326/0003-4819-137-10-200211190-00023.
  8. Bonkovsky H.L., Azar R., Bird S, et ai. Severe choiestatic hepatitis caused by thiazoiidinediones: risks associated with substituting rosigiitazone for trogiitazone. Dig Dis Sci. 2002;47(7):1632-37. doi: 10.1023/a:1015895925374.
  9. Tisdaie J.E., Miiier D.A. Drug-Induced Diseases: Prevention, Detection, and Management. Am J Pharm Educ. 3rd ed. 2018.
  10. Kapiowitz N, DeLeve L.D, eds. Drug-induced iiver disease. 3rd ed. Amsterdam: Eisevier, 2013. Doi: https://doi.org/10.1016/C2010-0-68917-6.
  11. Kutoh E. Possibiemetformin-inducedhepatotoxicity. Am J Geriatr Pharmacother. 2005;3(4):270-73.
  12. Saadi T, Waterman M, Yassin H, Baruch Y. Metformin-induced mixed hepatoceiiuiar and choiestatic hepatic injury: case report and iiterature review. Int J Gen Med. 2013;6:703-706. doi: 10.2147/IJGM.S49657
  13. Barquero Romero J., Perez Miranda M. Hepatitis coiestasica inducida por meftormina [Metformin-induced choiestatic hepatitis]. Gastroenteroi Hepatoi. 2005;28(4):257-58. doi: 10.1157/130 7309 7.
  14. Gupta R., Sachar D.B. Chiorpropamide-induced choiestatic jaundice and pseudomembranous coiitis. Am J Gastroenteroi. 1985;80(5):381-83.
  15. Rumboidt Z., Bota B. Favorabie effects of giibenciamide in a patient exhibiting idiosyncratic hepatotoxic reactions to both chiorpropamide and toibutamide. Acta Diabetoi Lat. 1984;21(4):387-91. doi: 10.1007/BF02582093.
  16. Wongpaitoon V., Miiis P.R., Russeii R.I., Patrick R.S. Intrahepatic choiestasis and cutaneous buiiae associated with giibenciamide therapy. Postgrad Med J. 1981 ;57(666):244-46. doi:10.1136/ pgmj.57.666.244.
  17. May L.D., Lefkowitch J.H., Kram M.T., Rubin D.E. Mixed hepatoceiiuiar-choiestatic iiver injury after piogiitazone therapy. Ann Intern Med. 2002;136(6):449-52. doi: 10.7326/0003-4819-136-6-200203190-00008.
  18. Fioyd J.S., Barbehenn E., Lurie P, Woife S.M. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2009;18(12):1238-1243. doi: 10.1002/ pds.1804.
  19. Ерёмина Е.Ю. Лекарственные поражения печени. Гастроэнтерология Санкт-Петербурга. 2012;(1):16-23.
  20. Садовникова И.В., Садовникова В.В. Клиникоэкспериментальное обоснование урсосанотерапии при токсическом медикаментозном гепатите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007;17(1):69
  21. Sundaram V, Bjornsson E.S. Drug-induced cholestasis. Hepatol Commun. 2017;1(8):726-35. doi: 10.1002/hep4.1088.
  22. Лазебник Л.Б., Звенигородская Л.А., Хомерики С.Г. и др. Лекарственный (статиновый) гепатит. Экспериментальная и клиническая и гастроэнтерология. 2009;(3): 110-16.
  23. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю. и др. Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность лечения статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей (исследование РАКУРС). Рациональная фармакотерапия в кардиологии. 2014;(10)2:147-52.
  24. Ивашкин В.Т, Жаркова М.С., Маевская М.В., Лапшин А.В. Случай тяжелого лекарственного гепатита, индуцированного длительным приемом кордарона. Российские медицинские вести. 2009;(2):78-83
  25. Сивякова О.Н., Шманова Н.Ю., Дулеба А.П. Случай множественных побочных эффектов амиодарона. Consilium Medicum. 2018;20(5):71-74. doi: 10.26442/2075-1753_2018.5.71-74
  26. Киякбаев Г.К. Аритмии сердца. Основы электрофизиологии, диагностика, лечение и современные рекомендации. Под. ред. В.С. Моисеева. М.: ГЭОТАР-Медиа, 2014
  27. Государственный реестр лекарственных средств Минздрава России. URL: http://grls. rosminzdrav.ru. (дата обращения/date of access: 10.07.2020).
  28. Официальный сайт международной базы данных нежелательных реакций ВОЗ VigiAccess. [The official site of the international database of adverse reactions WHO VigiAccess. (In Russ.)]. Available at: http://www.vigiaccess.org (дата обращения/date of access: 10.07.2020).
  29. Ratz Bravo A.E., Drewe J., Schlienger R.G., et al. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med. 2005;33(1):128-46. doi: 10.1097/01. ccm.0000151048.72393.44.
  30. Giannattasio F., Salvio A., Varriale M., et al. Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity. Ann Ital Med Int. 2002;17(3):180-84.
  31. Rhodes A., Eastwood J.B., Smith S.A. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Gut. 1993;34(4):565-66. doi: 10.1136/gut.34.4.565.
  32. James P.R., Hardman S.M. Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy. Heart. 1997;77(6):583-84. doi:10.1136/ hrt.77.6.583.
  33. Kicker J.S., Haizlip J.A., Buck M.L. Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant. J Pediatr Pharmacol Ther. 2012;17(2):189-95. doi: 10.5863/1551-6776-17.2.189.
  34. Nasser M., Larsen T.R., Waanbah B., et al. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf. 2013;5:191-98. doi: 10.2147/DHPS.S48640.
  35. Vassallo P, Trohman R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312-1322. doi: 10.1001/jama.298.11.1312.
  36. Heger J.J., Prystowsky E.N., Jackman W.M., et al. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981;305(10):539-45. doi:10.1056/ NEJM198109033051002.
  37. Lewis J.H., Ranard R.C., Caruso A., et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9(5):679-85. doi: 10.1002/ hep.1840090504.
  38. Mattar W., Juliar B., Gradus-Pizlo I., Kwo P.Y. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointestin Liver Dis. 2009;18(4):419-23.
  39. Llanos L., Moreu R., Peiro A.M., et al. Causality assessment of liver injury after chronic oral amiodarone intake. Pharmacoepidemiol Drug Saf. 2009;18(4):291-300. doi: 10.1002/pds.1709.
  40. Переверзев А.П., Остроумова О.Д. Лекарственно-ассоциированная жировая болезнь печени. Безопасность и риск фармакотерапии. 2020;(2):8:66-76. [
  41. Pendyala V.S. A Case of Amiodarone-induced Hepatitis and Review of the Literature J Hepatol Gastroint Dis. 2016;2(1):1-3. doi: 10.4172/2475-3181.1000120.
  42. Hussain N., Bhattacharyya A., Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943. doi: 10.1155/2013/617943.
  43. Chang C.C., Petrelli M., Tomashefski J.F. Jr, McCullough A.J. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med. 1999;123(3):251-56. doi: 10.1043/0003-9985(1999)123<0251:SICC BA>2.0.CO;2.
  44. Rabinowich L., Shibolet O. Drug Induced Steatohepatitis:An Uncommon CulpritofaCommon Disease. Biomed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905.
  45. Nemati M.H., Astaneh B. Amiodarone Versus Propafenone to Treat Atrial Fibrillation after Coronary Artery Bypass Grafting: A Randomized Double Blind Controlled Trial. Korean J Thorac Cardiovasc Surg. 2016;49(3):1 77-84. doi: 10.5090/kjtcs.2016.49.3.177.
  46. Петрова В.Б., Петрова А.И., Лаптева Е.С. Парентеральное введение лекарственных веществ. Внутривенная капельная инфузия. Взятие венозной крови. Постинъекционные осложнения. (Часть 2). Учебно-методическое пособие. СПб.: Изд-во СЗГМУ им. И.И. Мечникова, 2013. 44 с.
  47. Treglia A., Alfano C., Rossini E. Confronto tra propafenone ed amiodarone nella conversione al. ritmo sinusale della fibrillazione atriale di recente insorgenza [A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset]. Minerva Cardioangiol. 1994;42(6):293-97.
  48. Yi-Shin Huang. The Therapeutic Efficacy of Ursodeoxy-cholic Acid (UDCA) in Drug-induced Liver injury: Results of a Randomized Controlled Trial. Available at: https://www. gastrojournal.org/ article/S0016-5085(10)63727-4/pdf. (date of access: 10.07.2020).
  49. Wree A., Dechne A., Herzer K., et al. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54-59. doi: 10.1159/ 000322298.
  50. Lang S.M., Ortmann J., Rostig S., Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. int J Mycobacteriol. 20 19;8( 1 ):89-92. doi: 10.4103/ijmy. ijmy_159_18.
  51. FAN Shu-bing, FAN Shu-qi. Effect of ursodeoxycholic on drug-induced liver injury. Available at: http://en.cnki.com.cn/Article_en/ CJFDTotal-JLYX201129026.htm (date of access: 06.07.2020).
  52. Ивашкин В.Т, Барановский А.Ю., Райхельсон К.Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):101-131. Doi: https://doi.org/10.22416/1382-4376-2019-29-1-101-131.
  53. Mohankumar N., Ranjan P, Kumari A. Drug-induced liver injury: Diagnosing (and treating) it early. J Fam Pract. 2015;64(10):634-44.
  54. Devarbhavi H. An Update on Drug-induced Liver injury J Clin Exp Hepatol. 2012;2(3):247-59. doi: 10.1016/j.jceh.2012.05.002.
  55. de Caestecker J.S., Jazrawi R.P., Petroni M.L., Northfield T.C. Ursodeoxycholic acid in chronic liver disease. Gut. 1991;32(9): 1061-1065. doi:10.1136/ gut.32.9.1061
  56. Ивашкин В.Т., Широкова Е.Н., Маевская М.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;(2):41-57.
  57. Лазебник Л.Б., Голованова Е.В., Хлынова О.В. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;2(174):29-54. doi: 10.31146/1682-8658-ecg-174-2-2954
  58. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-267. doi: 10.1016/j. jhep.2009.04.009.
  59. Nathwani R.A., Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis. 2006;10(2):207-vii. doi: 10.1016/j. cld.2006.05.009.
  60. Liu L.W., Zhao X.Y., Jia J.D. [EASL clinical practice guidelines recommendations for drug-induced liver injury in 2019]. Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):420-423. Chinese. doi: 10.3760/cma.j.issn.1007-3418.2019.06.006.
  61. European Association for the Study of the Liver. Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-1261. doi: 10.1016/j.jhep.2019.02.014.
  62. LiverTox® - ресурс для специалистов практического здравоохранения по вопросам лекарственнного поражения печени. URL: https://iivert.ox.nih.gov/ Phenotypes_iact.htmi (дата обращения/date of access: 16.05.2020)

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2020

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies